Benitec Biopharma Inc. (BNTC)
11.71
0.52 (4.65%)
At close: Feb 20, 2025, 3:59 PM
11.57
-1.20%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 11.37 |
| Market Cap | 274.62M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | -18.89 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11.89 |
| Volume | 17,794 |
| Avg. Volume (20D) | 52,316 |
| Open | 11.10 |
| Previous Close | 11.19 |
| Day's Range | 10.92 - 11.83 |
| 52-Week Range | 3.28 - 13.29 |
| Beta | undefined |
About BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company w...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 24, 2014
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BNTC
Website https://benitec.com
Analyst Forecast
According to 6 analyst ratings, the average rating for BNTC stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 104.95% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 days ago
+15.98%
Benitec Biopharma shares are trading higher follow...
Unlock content with
Pro Subscription
9 months ago
-12.22%
Benitec Biopharma shares are trading lower after the company reported worse-than-expected Q3 GAAP EPS results and a year-over-year decrease in Q3 revenue results.
